Getein Biotech

Getein Biotech P/TBV

The Price to Tangible Book Value (P/TBV) of Getein Biotech (603387.SS) as of Oct 29, 2026 is 1.61. In the previous year, Price to Tangible Book Value (P/TBV) was 1.81 — a change of -11.40% (lower).

P/TBV

1.61

YoY

-11.40%

Last updated:

Price to Tangible Book Value (P/TBV) of Getein Biotech is 2025 1.61 . Price to Tangible Book Value (P/TBV) of Getein Biotech was 2024 1.81 . It decreases by -11.40% lower compared to the previous year.

The Getein Biotech P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2018
3.35 CNY
Jan 1, 2019
2.78 CNY
Jan 1, 2020
2.55 CNY
Jan 1, 2021
2.23 CNY
Jan 1, 2022
1.90 CNY
Jan 1, 2023
1.87 CNY
Jan 1, 2024
1.81 CNY
Jan 1, 2025
1.61 CNY
The Getein Biotech P/TBV history
YEARP/TBVYoY
1.61-11.40%
1.81-3.17%
1.87-1.55%
1.90-14.69%
2.23-12.34%
2.55-8.30%
2.78-17.15%
3.35-15.02%
3.94-71.83%
13.99-21.91%
17.92-38.29%
29.04—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Getein Biotech Stock analysis

What does Getein Biotech do? Getein Biotech Inc generates revenue through the sale of in vitro diagnostic reagents and diagnostic instruments. The company offers POCT reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, and hemagglutination reagents. Diagnostic instruments include the FIA 8000 and FIA 8600 immunoquantitative analyzers, Getein 1100 and Getein 1180 fluorescence immunoquantitative analyzers, CM 400 automatic biochemical analyzer, MAGICL 6000 automatic chemiluminescence analyzer, and BHA-5000 five classification blood cell analyzer. The firm also provides testing and agency services. Products are distributed domestically and to overseas markets. The primary buyers of Getein Biotech's products include healthcare facilities, laboratories, and medical institutions within China and international markets. Domestic sales focus on the Chinese healthcare sector, while overseas markets extend to global customers seeking diagnostic solutions. The company's reagent and instrument portfolio targets hospitals, clinics, and diagnostic centers requiring reliable testing equipment and consumables. Getein Biotech's revenue streams are derived from direct sales of its diagnostic reagents and instruments, as well as service-based offerings like testing and agency services. The company's product range caters to both domestic and international healthcare providers, with a strong emphasis on in vitro diagnostic solutions for blood analysis, chemiluminescence, and biochemical testing. The firm's distribution strategy ensures its products reach medical facilities across China and internationally. Getein Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Getein Biotech stock

Price to Tangible Book Value (P/TBV) of Getein Biotech is 1.61 in 2025.

Price to Tangible Book Value (P/TBV) of Getein Biotech changed from 1.81 to 1.61, representing a -11.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Getein Biotech since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Getein Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Getein Biotech

All Key Metrics — Getein Biotech